Second generation antipsychotics have developed a reputation for being more effective for treating a number of the symptoms of schizophrenia than their first generation counterparts, even if research doesn’t always back up this claim.
Read More
Since antidepressants and psychotherapy are about equally effective for mild to moderate depression, how do we decide which to use for a given patient?
Read More
It seems that drug-drug interactions (DDI) were in our profession’s consciousness more in the past than they are now. Is this because we have less to worry about than we used to?
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
